Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset.

Selimoglu-Buet D, Rivière J, Ghamlouch H, Bencheikh L, Lacout C, Morabito M, Diop M, Meurice G, Breckler M, Chauveau A, Debord C, Debeurme F, Itzykson R, Chapuis N, Willekens C, Wagner-Ballon O, Bernard OA, Droin N, Solary E.

Nat Commun. 2018 Dec 21;9(1):5455. doi: 10.1038/s41467-018-07801-x.

2.

T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.

Belhadj M, Mansour D, Kaltenbach S, Deau-Fischer B, Franchi P, Tamburini J, Chapuis N, Damotte D, Kosmider O, Burroni B, Bouscary D.

Haematologica. 2019 Mar;104(3):e117-e120. doi: 10.3324/haematol.2018.205542. Epub 2018 Dec 20. No abstract available.

3.

Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis.

Tarfi S, Harrivel V, Dumezy F, Guy J, Roussel M, Mimoun A, Fenaux P, Chapuis N, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myélodysplasies (GFM).

Blood Cancer J. 2018 Nov 14;8(11):114. doi: 10.1038/s41408-018-0146-8.

4.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

5.

CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, Lauf J, Alary AS, Burroni B, Kosmider O, Fontenay M, Béné MC, Durrieu F, Bettelheim P, Bardet V.

Br J Haematol. 2019 Feb;184(4):625-633. doi: 10.1111/bjh.15584. Epub 2018 Sep 10.

PMID:
30198568
6.

Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.

Ogata K, Sei K, Saft L, Kawahara N, Porta MGD, Chapuis N, Yamamoto Y.

Leuk Res. 2018 Aug;71:75-81. doi: 10.1016/j.leukres.2018.07.009. Epub 2018 Jul 10.

PMID:
30025279
7.

Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening.

Daix T, Guerin E, Tavernier E, Mercier E, Gissot V, Hérault O, Mira JP, Dumas F, Chapuis N, Guitton C, Béné MC, Quenot JP, Tissier C, Guy J, Piton G, Roggy A, Muller G, Legac É, de Prost N, Khellaf M, Wagner-Ballon O, Coudroy R, Dindinaud E, Uhel F, Roussel M, Lafon T, Jeannet R, Vargas F, Fleureau C, Roux M, Allou K, Vignon P, Feuillard J, François B; Septiflux Trial Group.

Chest. 2018 Sep;154(3):617-627. doi: 10.1016/j.chest.2018.03.058. Epub 2018 Apr 26.

PMID:
29705219
8.

A pernicious mean corpuscular volume.

Green AS, Chapuis N.

Blood. 2018 Jan 25;131(4):472. doi: 10.1182/blood-2017-09-807149. No abstract available.

9.

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, Rousseau A, Fenaux P, Chevret S, Chapuis N, Boeva V, Fridman WH, Fontenay M, Kosmider O.

Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3. No abstract available.

PMID:
28972593
10.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
11.

Plasma cell leukemia revealing a G6PD deficiency.

Raimbault A, Chapuis N.

Blood. 2016 Dec 29;128(26):3178. doi: 10.1182/blood-2016-08-736322. No abstract available.

12.

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Chesnais V, Arcangeli ML, Delette C, Rousseau A, Guermouche H, Lefevre C, Bondu S, Diop M, Cheok M, Chapuis N, Legros L, Raynaud S, Willems L, Bouscary D, Lauret E, Bernard OA, Kosmider O, Pflumio F, Fontenay M.

Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16.

13.

Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.

Ohayon D, De Chiara A, Chapuis N, Candalh C, Mocek J, Ribeil JA, Haddaoui L, Ifrah N, Hermine O, Bouillaud F, Frachet P, Bouscary D, Witko-Sarsat V.

Sci Rep. 2016 Oct 19;6:35561. doi: 10.1038/srep35561.

14.

Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore study.

Sauneuf B, Bouffard C, Cornet E, Daubin C, Brunet J, Seguin A, Valette X, Chapuis N, du Cheyron D, Parienti JJ, Terzi N.

Ann Intensive Care. 2016 Dec;6(1):65. doi: 10.1186/s13613-016-0170-4. Epub 2016 Jul 16.

15.

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1.

PMID:
27378568
16.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

17.

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B.

Oncotarget. 2016 Jun 14;7(24):35753-35767. doi: 10.18632/oncotarget.7099.

18.

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.

Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Huillard O, Boudou-Rouquette P, Fontenay M, Goldwasser F, Alexandre J.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1033-9. doi: 10.1007/s00280-015-2875-8. Epub 2015 Sep 29.

PMID:
26420236
19.

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, Goldwasser F, Mortier L, Dupin N, Blanchet B.

Target Oncol. 2016 Feb;11(1):59-69. doi: 10.1007/s11523-015-0375-8.

PMID:
26208946
20.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

21.

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Bardet V, Wagner-Ballon O, Guy J, Morvan C, Debord C, Trimoreau F, Benayoun E, Chapuis N, Freynet N, Rossi C, Mathis S, Gourin MP, Toma A, Béné MC, Feuillard J, Guérin E; Groupe Francophone des Myélodysplasies (GFM); Groupe d’Etude Immunologique des Leucémies (GEIL).

Haematologica. 2015 Apr;100(4):472-8. doi: 10.3324/haematol.2014.112755. Epub 2015 Jan 30.

22.

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V.

Cytometry B Clin Cytom. 2015 Mar;88(2):101-9. doi: 10.1002/cyto.b.21200. Epub 2014 Nov 17.

23.

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V.

Cytometry B Clin Cytom. 2014 Oct 28. doi: 10.1002/cytob.21200. [Epub ahead of print]

24.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.

25.

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.

Mathis S, Chapuis N, Debord C, Rouquette A, Radford-Weiss I, Park S, Dreyfus F, Lacombe C, Béné MC, Kosmider O, Fontenay M, Bardet V.

Leukemia. 2013 Oct;27(10):1981-7. doi: 10.1038/leu.2013.178. Epub 2013 Jun 14.

PMID:
23765225
26.

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.

Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, Cahn JY, Leguay T, Bories P, Witz F, Lamy T, Mayeux P, Lacombe C, Demur C, Tamburini J, Merlat A, Delepine R, Vey N, Dreyfus F, Béné MC, Ifrah N, Bouscary D; GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang).

Leukemia. 2013 Jul;27(7):1479-86. doi: 10.1038/leu.2013.17. Epub 2013 Jan 16.

PMID:
23321953
27.

Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.

Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, Tamburini J, Fontenay M, Bouscary D.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):347-50. doi: 10.1016/j.clml.2012.11.007. No abstract available.

PMID:
23246161
28.

A dramatic fetal outcome following transplacental transfer of dasatinib.

Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N, Tsatsaris V.

Anticancer Drugs. 2012 Aug;23(7):754-7. doi: 10.1097/CAD.0b013e328352a8fe.

PMID:
22421368
29.

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D.

Curr Oncol Rep. 2012 Apr;14(2):129-38. doi: 10.1007/s11912-012-0227-y. Review.

PMID:
22350330
30.

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6.

PMID:
22143671
31.

The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia.

Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Br J Haematol. 2012 Feb;156(4):547-50. doi: 10.1111/j.1365-2141.2011.08891.x. Epub 2011 Oct 14. No abstract available.

PMID:
21995271
32.

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V.

Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20.

33.

Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.

Al-Nawakil C, Park S, Chapuis N, Dreyfus F, Szwebel TA, Gibault L, Molina T, Hermine O, Bouscary D, Tamburini J.

Br J Haematol. 2012 Jan;156(1):145-7. doi: 10.1111/j.1365-2141.2011.08825.x. Epub 2011 Aug 16. No abstract available.

PMID:
21848881
34.

LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.

Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Cell Cycle. 2011 Jul 1;10(13):2115-20. Epub 2011 Jul 1. Review.

PMID:
21572254
35.

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.

Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102. Epub 2010 Sep 30.

36.

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.

Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D.

Leukemia. 2010 Oct;24(10):1686-99. doi: 10.1038/leu.2010.170. Epub 2010 Aug 12. Review.

PMID:
20703258
37.

Insulin receptor A and IGF-1R in AML - Letter.

Chapuis N, Lacombe C, Tamburini J, Bouscary D, Mayeux P.

Cancer Res. 2010 Sep 1;70(17):7010; author reply 7010. doi: 10.1158/0008-5472.CAN-10-0136. Epub 2010 Aug 10. No abstract available.

38.

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.

Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N, Dreyfus F, Bismuth G, Baud V, Lacombe C, Mayeux P, Bouscary D.

Blood. 2010 Nov 18;116(20):4240-50. doi: 10.1182/blood-2009-12-260711. Epub 2010 Jul 29.

39.

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.

Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Blood. 2010 Nov 18;116(20):4262-73. doi: 10.1182/blood-2010-02-269837. Epub 2010 Jul 28.

40.

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Haematologica. 2010 Mar;95(3):415-23. doi: 10.3324/haematol.2009.010785. Epub 2009 Dec 8.

41.

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D.

Haematologica. 2010 May;95(5):819-28. doi: 10.3324/haematol.2009.013797. Epub 2009 Nov 30. Review.

42.

Targeting translation in acute myeloid leukemia: a new paradigm for therapy?

Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, Bouscary D.

Cell Cycle. 2009 Dec;8(23):3893-9. Review.

PMID:
19934662
43.

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D.

Blood. 2009 Aug 20;114(8):1618-27. doi: 10.1182/blood-2008-10-184515. Epub 2009 May 20.

44.

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C, Park S, Choquet S, Dreyfus F, Bouscary D.

Leuk Lymphoma. 2008 Oct;49(10):2012-4. doi: 10.1080/10428190802290660. No abstract available.

PMID:
18720213
45.

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Leukemia. 2008 Sep;22(9):1698-706. doi: 10.1038/leu.2008.144. Epub 2008 Jun 12.

PMID:
18548104
46.

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Blood. 2008 Jan 1;111(1):379-82. Epub 2007 Sep 18.

47.

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Blood. 2007 Aug 1;110(3):1025-8. Epub 2007 Apr 10.

48.

Molecular characterization of a novel mutation in the factor XIII A subunit gene associated with a severe defect and an adulthood diagnosis.

Trigui N, Frère C, D'Ercole C, Chambost H, Chapuis N, Pouymayou C, Morange P, de Mazancourt P.

Haemophilia. 2007 Mar;13(2):221-2. No abstract available.

PMID:
17286781
49.

The esterase-like activity of serum albumin may be due to cholinesterase contamination.

Chapuis N, Brühlmann C, Reist M, Carrupt PA, Mayer JM, Testa B.

Pharm Res. 2001 Oct;18(10):1435-9.

PMID:
11697469
50.

Estimation of passive horizontal linear whole-body displacement in humans.

Israël I, Chapuis N, Glasauer S, Charade O, Berthoz A.

J Neurophysiol. 1993 Sep;70(3):1270-3.

PMID:
8229174

Supplemental Content

Loading ...
Support Center